SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances higher full-year revenue guidance, attributed to sustained demand for Amtagvi and Proleukin, is driving attention as traders view it as evidence of commercial growth and improving execution. The reaction is broadly bullish, though some question whether the update is already priced in and look to upcoming lung-cancer data as another catalyst.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQures additional 48-month AMT-130 data for Huntingtons disease is driving attention: cUHDRS slowing weakened versus the 36-month results and did not reach statistical significance, prompting a sharp selloff. Traders debate whether the longer-term results reflect patient dropouts and changes in the external comparator, while bulls argue the FDA-aligned 36-month data remains the basis for the accelerated-approval filing.

Fair Isaac Corp. engages in the provision of decision management solutions. It operates through the Software and Scores segments. The Software segment includes pre-configured analytic and decision management solutions designed for a specific type of business need or process. The Scores segment focuses on business-to-business scoring solutions and services, business-to-consumer scoring solutions and services including myFICO solutions for consumers and associated professional services. The company was founded by Bill Fair and Earl Isaac in 1956 and is headquartered in San Jose, CA.

Fair Isaac Corp.

Fair, Isaac Corp.

FHFA moves to let Fannie Mae and Freddie Mac use VantageScore alongside FICO are fueling concern that cheaper competition could erode FICOs longstanding mortgage-scoring advantage and pricing power. Traders remain divided between viewing the selloff as an overreaction given FICOs broader business and seeing competitive and regulatory pressure as a threat to its valuation.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

AstraZenecas strategic investment in Summit and clinical collaboration to test ivonescimab in gastrointestinal cancers are driving attention, with traders viewing the deal as financing relief and a strong vote of confidence. Some caution that it is not an acquisition and that the separate FDA decision remains uncertain, while others warn of a possible sell-the-news reaction.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas selection for the U.S. Armys ALATTIS program to develop ultra-high-voltage silicon carbide devices and validate domestic manufacturing is driving attention. Bulls see the award as meaningful technology and government validation, while skeptics note it is a prototype program with no disclosed financial terms or clear near-term revenue; short-squeeze hopes and sell-the-news concerns add to the debate.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

A sharp rebound has fueled breakout chatter, with bullish traders pointing to Zebecs payroll and payments partnershipsincluding MoneyGramas support for its adoption story. Others remain skeptical about weak price follow-through and real-world usage, while speculation about a Robinhood tie-up is unconfirmed.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Immix reported an 89% complete-response rate in the 45-patient NEXICART-2 update, with all 25 newer patients in complete response or MRD-negative and no relapses or neurotoxicity reported to date. Traders welcomed the clinical results but debated the concurrent registered offering and its potential dilution.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

AVAXs sharp rally and rising volume have revived breakout talk, with traders pointing to broader altcoin momentum and the tokenization/institutional-adoption narrative, including reported NYSE testing of Avalanche technology. Others doubt the move is supported by lasting demand and warn it could fade as a speculative pump.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

CROs sharp rebound toward the seven-cent resistance level has fueled breakout talk, with traders pointing to Crypto.coms reported Citadel Securities investment and Cronos app plans as possible tailwinds. Others question whether the move can hold, citing concerns about token supply expansion and Crypto.com leadership.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Kodiaks positive late-stage wet AMD results have pressured OCUL on concerns that stronger competition could challenge AXPAXLIs prospects. Traders debate whether the trials are comparable, with bulls arguing AXPAXLIs durability and distinct study design limit the read-through, while others worry about its competitive position.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

VWAGY Flags Major Charges as Porsche and China Pressure Hits Profit 

Volkswagen flags EUR 10 billion in 2026 charges, driven by Porsche weakness, China challenges and restructuring as its profit outlook sharply falls. 

Is Custom Truck One Source (CTOS) Stock Outpacing Its Auto-Tires-Trucks Peers This Year?

Here is how Custom Truck One Source, Inc. (CTOS) and Dorman Products (DORM) have performed compared to their sector so far this year.

Here's Why Custom Truck One Source (CTOS) is Poised for a Turnaround After Losing 19.5% in 4 Weeks

The heavy selling pressure might have exhausted for Custom Truck One Source (CTOS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

New Strong Buy Stocks for September 2nd

LCUT, CURI, OSCR, CTOS and CHYM have been added to the Zacks Rank #1 (Strong Buy) List on September 2, 2026.

Is Custom Truck One Source (CTOS) Outperforming Other Auto-Tires-Trucks Stocks This Year?

How Much Upside is Left in Custom Truck One Source (CTOS)? Wall Street Analysts Think 25.07%

The mean of analysts' price targets for Custom Truck One Source (CTOS) points to a 25.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks.com featured highlights include Superior Group of Companies, AMC Global Media and Custom Truck One Source

Three breakout candidates stand out for August, with Superior Group, AMC Global Media and Custom Truck showing strong earnings growth.

3 Breakout Stocks Poised for Big Gains This August

Breakout candidates SGC, AMCX and CTOS are trading near 52-week highs after passing technical screens. See why they could gain in August.

Micron & 2 Profitable Stocks Smart Investors Are Buying in August 

Micron, BrightSpring Health and Custom Truck One Source combine strong profitability with earnings growth. See why they stand out in August. 

What Makes Custom Truck One Source (CTOS) a New Strong Buy Stock

Custom Truck One Source (CTOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Custom Truck One Source, Inc. engages in the sale and rental of truck and heavy equipment. The firm offers aftermarket parts and service, equipment customization, remanufacturing, financing solutions, and asset disposal services. The company was founded in 1996 and is headquartered in Kansas City, MO.

Custom Truck One Source Inc

Bullish Sentiment

Adding risk (buying more)

Trimming/taking profits

Rotating into safer assets

Staying the course, no changes

We&#39;re about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Stocktwits

We're about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Current Price	$9.31
Prev Close	$9.45
Open	$9.41
Dividend Yield	0.00%
50-Day Moving Average	$9.85
Beta	1.59
Avg. Volume	935,826.76
PE Ratio	99.15

52-Week High	$12.23
52-Week Low	$5.18
Market Capitalization	$2.15B
EPS (Annual)	-$0.1368
Price to Book	2.60
Revenue Per Employee	$777,582.80

Feed

News

Sentiment

Earnings

Fundamentals

Info

CTOS Fundamentals